Search

Displaying results 4511 - 4520 of 10000 in total
  1. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc

  2. Drug

    Setiptiline

    go.drugbank.com/drugs/DB09304
    Experimental

    In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.

  3. Drug

    INCB7839

    go.drugbank.com/drugs/DB05033
    Investigational

    It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.

  4. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    autoimmune hemolysis that are often observed in CHAPLE disease. … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.

  5. Drug

    INS 316

    go.drugbank.com/drugs/DB05390
    Experimental

    INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer.

  6. Drug

    Tallimustine

    go.drugbank.com/drugs/DB15466
    Experimental

    [A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as [brostallicin], which have a favourable cytotoxicity … Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA.

  7. Drug

    Treamid

    go.drugbank.com/drugs/DB16365
    Investigational

    It is has been investigated in the clinical trials of NCT04428593 (Study to Assess Safety, Tolerability and Pharmacokinetics of Treamid in Healthy Volunteers) and NCT04527354 (Pilot Study to Assess Efficacy … and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia) by PHARMENTERPRISES.

  8. Drug

    PRLX 93936

    go.drugbank.com/drugs/DB06098
    Investigational

    PRLX 93936 is selectively toxic to cancer cells.

  9. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.

  10. Drug

    Neocartilage

    go.drugbank.com/drugs/DB05257
    Investigational

    Neocartilage is the only scaffold-free living cartilage graft on the market.